Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC POTASSIUM versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC POTASSIUM versus NAPROSYN.
DICLOFENAC POTASSIUM vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
50 mg orally twice daily or 75 mg orally once daily; maximum 150 mg/day. Alternatively, 75 mg intramuscularly once daily (short-term).
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is ~1.1 hours (range 0.9–1.6 h). Short half-life supports frequent dosing (e.g., every 6–8 hours) for sustained analgesia.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Approximately 50% of a dose is eliminated via first-pass hepatic metabolism; renal excretion accounts for ~65% of the administered dose as metabolites (<1% unchanged drug); fecal excretion <20%.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID